The Number That Made the Stock Look Like It Was Growing

The Number That Made the Stock Look Like It Was Growing

Procept BioRobotics told investors it was selling thousands of medical devices every quarter. Its handpiece unit sales grew at an 85% compound annual rate from 2022 to 2025. Revenue climbed 37% in fiscal 2025 alone. The growth trajectory looked like proof of demand.

The problem is that the number everyone was watching measured what hospitals ordered, not what they used.

Procept sells a robotic surgery system for treating enlarged prostates — the Aquablation therapy, now on the Hydros platform. The machines cost hospitals roughly $450,000 to $500,000 each. But the recurring revenue comes from single-use handpieces: disposable surgical tools priced around $3,200 per unit, now pushed toward $3,550. Each procedure uses one handpiece. The company has 765 of these machines installed across U.S. hospitals.

If you've ever wondered why medical device stocks command premium valuations, it's this structure. Sell the expensive system once. Then earn recurring revenue on every procedure, year after year. The handpiece is the heartbeat. It's supposed to be a clean proxy for how many patients are getting treated.

Procedures up, handpieces up. They should be the same number.

The picture most investors carried is that the two were tracking together. The lawsuit alleges they never were.

Here's the ordinary version

A restaurant franchise sells special sauce packets to its locations. Each meal uses one packet. Every quarter, the corporate office offers a steep discount if locations buy 20% more packets than they expect to need. The locations take it. Who doesn't want a discount? The corporate quarterly report shows a surge in packets shipped — great growth! Investors cheer.

Then the discount stops. Next quarter, orders collapse because the restaurants' walk-ins are already full of sauce packets from the previous quarter. The corporate office shipped the same packets twice in its reports but counted them only in the quarter when the discount ran. The future was borrowed and pasted onto the present.

The restaurant's actual meal count never grew at the headline rate. It grew at the rate of meals served. The packet shipments were just inventory in someone else's parking lot.

Now label the props.

• Restaurant franchise → Procept BioRobotics
• Individual locations → U.S. hospitals that bought the robotic system
• Sauce packets → Single-use handpieces
• Meals served → Actual procedures performed
• Discount for bulk orders → Procept's undisclosed end-of-quarter purchasing incentive program
• Packets sitting in the walk-in → Handpieces sitting in hospital inventory, never used

The discount program, offered in the final weeks of each quarter, incentivized hospitals to place bulk handpiece orders beyond their expected procedure volumes. Procept shipped those handpieces, booked the revenue, and reported the unit sales. The handpieces sat in hospital supply closets. Future quarters had fewer orders because hospitals already had enough handpieces on the shelf.

Management told investors the opposite was happening. In May 2024, CFO Kevin Waters said customers "tend to order as they need" product and there had been "no changes in trends between handpieces sold and procedures" In August 2025, when pressed about the ratio, Waters said the differential had "remained relatively consistent" throughout Procept's time as a public company.

The three quarters the story unraveled

The discount program didn't collapse at once. It leaked out through three consecutive earnings calls, each followed by a stock crash.

August 2025 — Q2 results showed 12,750 handpieces shipped. Guidance for the next quarter was set at 13,350 units, well below what analysts expected. Procept eliminated its chief commercial officer role. Stock fell 16% over two days.

November 2025 — Q3 shipped 13,225 handpieces, missing guidance. Management cut full-year handpiece guidance by 1,000 units to allow for "optimization of field inventory". CEO Larry Wood admitted Procept had not "been managing customer inventory by establishing par levels" and some customers were "probably carrying too much" inventory. Stock fell 10%..

February 2026 — The full accounting. Procept disclosed for the first time how many actual procedures had been performed over the prior three years. The answer: handpiece sales had exceeded procedures in every quarter since the first quarter of 2023. The gap had been growing. Cumulative excess field inventory topped 10,000 units. U.S. handpiece sales fell nearly 30% sequentially from Q3 to Q4 — from 13,225 units to 9,400. Management confirmed it was eliminating the discount program. Stock fell 18%.

From the August 2025 peak through February 2026, Procept stock dropped 48%. It would trade below $18 by mid-2026. At $21.27 today, the stock is down 32% year-to-date and has lost nearly half its value over the trailing twelve months.

The real numbers, finally side by side

The February 2026 disclosure gave investors something they should have had from the start: procedure counts. Here's what Q4 2025 actually looked like.

• Procedures performed: 12,200 — a 69% year-over-year increase, the highest quarterly procedure volume in Procept's history
• Handpieces sold: 9,400 — up only 7% year-over-year
• The ratio: For the first time in the public disclosures, handpieces fell below procedures. The company had finally run through its field inventory problem.

During the discount era, handpiece sales were 8% to 16% above procedures every quarter. The company was selling handpieces that nobody was using yet. Revenue was pulled forward. The growth looked real because the revenue booked was real — the company shipped real handpieces that hospitals paid for. But the growth was borrowed from future quarters, and future quarters paid the bill.

What's different now

Procept eliminated the discount program and restructured its commercial organization. The handpiece-to-procedure ratio in Q1 2026 was 95%. In Q2 2026 it was 98%. Management's target is 1:1 going forward — the number should now approximate what it was supposed to mean from the beginning.

The second quarter 2026 results, reported August 4, showed total revenue of $94.5 million, up 19% year-over-year. U.S. procedures surpassed 13,100, up 21%. Handpiece ASP reached $3,550, an 11% increase year-over-year. Gross margin improved to 66%.

But the growth rate dropped. Procept cut its full-year U.S. procedure guidance from 39-48% down to 25-29%. The adjusted EBITDA loss forecast widened from a $17-$30 million range to $30-$35 million. The company is spending heavily on commercial expansion, the WATER IV prostate cancer trial, and BPH platform innovation — $350 million in operating expenses for the full year.

Revenue grew 19%. The company burned roughly $85 million in free cash flow over the trailing twelve months. Cash on hand sits at approximately $228 million.

The question the lawsuit doesn't answer

The securities class action, filed by the Operating Engineers Construction Industry and Miscellaneous Pension Fund with a lead plaintiff deadline of September 22, 2026, focuses on whether Procept misled investors about its financial performance. The class period runs from February 28, 2024 through February 25, 2026.

But the legal question is separate from the investment question: Is the underlying procedure demand strong enough to support the business at its current valuation, now that the growth metric investors were watching actually measures what it's supposed to measure?

Procept trades at a market cap of $1.2 billion against $308 million in fiscal 2025 revenue — roughly 3.6 times trailing sales. That's a premium multiple for a company losing $85 million in annual free cash flow with no path to profitability visible in the current guidance. The enterprise value is $1.04 billion after accounting for net cash.

The case for Procept rests on three things: procedures continue growing at 25% or more as more hospitals activate the system and urology guidelines strengthen their recommendation; handpiece pricing holds at the $3,500 level or higher, supporting the 65% gross margin target; and the WATER IV prostate cancer trial, which completed patient enrollment in July, opens an addressable market far larger than benign prostatic hyperplasia.

The risk is the other side of the same coin: procedure growth slows as the 765-system install base matures, meaning the high-growth quarters that built the stock price were partly inflated by the very practice the company just stopped. The $350 million operating expense budget assumes aggressive commercial expansion continues to pay off. A cash burn rate of $85 million per year against a $228 million balance means the runway is real but not unlimited.

The number everyone should watch now

Before the discount program, investors watched handpiece unit sales as a growth signal. The lawsuit argues that signal was contaminated. Now that handpieces align with procedures, procedure volume itself becomes the number. Not handpieces shipped. Procedures performed.

The ratio matters less when it's at 98%. What matters is whether 13,100 procedures per quarter grows to 14,000 next quarter and 15,000 the quarter after that — or whether it flattens. The install base grew 42% year-over-year to 765 systems. But new systems only help if they're being used. Procept says Hydros systems generate significantly higher procedure volumes than legacy AquaBeam machines. That's an execution claim, not a guarantee.

That analogy has done its job. Here is where it breaks. The restaurant example assumes hospitals buy handpieces the way restaurants buy sauce — passively, without a strategic reason. Real hospitals manage capital budgets, surgeon workflows, and procurement cycles. Some inventory surplus may reflect rational stocking behavior, not just a discount response. And Procept's pricing discipline is a genuine change — the $3,550 handpiece price is real revenue per unit, not a pulled-forward illusion. The lawsuit alleges misrepresentation; it does not prove the underlying demand was fake, only that the headline growth number included a borrowed component.

The reusable test: when Procept reports next quarter, look at U.S. procedures. That's the sauce packets actually consumed. Everything else — the revenue line, the margin, the valuation — flows from whether that number keeps climbing on its own weight.